Vitamin K-antagonistic effect of plastoquinone and ubiquinone derivatives in vitro.

FEBS Lett

IIIrd Department of Internal Medicine, Moabit Hospital, Berlin, Germany.

Published: January 1994

Decyl-ubiquinone and decyl-plastoquinone were used as model compounds to test the potential effect of quinone derivatives on two enzymes of the vitamin K cycle in vitro. Substantial inhibition of gamma-glutamate carboxylase was found, whereas vitamin K-epoxide reductase was inhibited to a much lesser extent. The inhibitory effect of both decylquinones was eliminated in a time-dependent way by solubilized microsomes, but not by purified carboxylase. Since a wide variety of prenylquinones occur as micronutrients, these results are of potential relevance for the effects of natural quinones in the human diet.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0014-5793(94)80352-8DOI Listing

Publication Analysis

Top Keywords

vitamin k-antagonistic
4
k-antagonistic plastoquinone
4
plastoquinone ubiquinone
4
ubiquinone derivatives
4
derivatives vitro
4
vitro decyl-ubiquinone
4
decyl-ubiquinone decyl-plastoquinone
4
decyl-plastoquinone model
4
model compounds
4
compounds test
4

Similar Publications

Background: The success of antithrombotic therapies is assessed based on thrombotic and bleeding events. Simultaneously assessing both kinds of events might be challenging, and recurrent bleeding events are often ignored. We tried to confirm the effects of kidney function on outcome events in patients undergoing antithrombotic therapy.

View Article and Find Full Text PDF

High prevalence of atrial fibrillation among Greenlanders with ischemic stroke - atrial fibrillation found in more than 30% of cases.

Int J Circumpolar Health

September 2014

Queen Ingrid's Health Center, Nuuk, Greenland ; Greenland Center for Health Research, University of Nuuk, Nuuk, Greenland.

Objectives: To estimate the prevalence of atrial fibrillation among Greenlanders with ischemic stroke.

Study Design: A cross-sectional study.

Methods: Information on atrial fibrillation and vitamin K antagonistic treatment at admittance and at discharge was obtained for Greenlanders admitted to Queen Ingrid's Hospital in Nuuk with an ischemic stroke in 2011 or in 2012 with methods described in details elsewhere.

View Article and Find Full Text PDF

CYP2C9 is the major human enzyme of the cytochrome P450 2C subfamily and metabolizes approximately 10% of all therapeutically relevant drugs. Two inherited SNPs termed CYP2C9*2 (Arg144Cys) and *3 (Ile359Leu) are known to affect catalytic function. Numerous rare or functionally silent polymorphisms have been identified.

View Article and Find Full Text PDF

[New developments in anticoagulation therapy for Ione atrial fibrillation].

Hamostaseologie

August 2002

II. Medizinische Klinik & Poliklinik, Johannes-Gutenberg-Universität, Mainz, Germany.

Lone atrial fibrillation is a major health problem for elderly patients with cardiovascular risk factors as hypertension, congestive heart failure or previous myocardial infarction. The increased stroke rate of these patients is significantly reduced by oral anticoagulation (target: INR 2-3) and less effective by acetylsalicylic acid at a dose of 325 mg/d. As an alternative to the vitamin K-antagonistic anticoagulants currently the SPORTIF trial program is performed investigating the safety and efficacy of the oral direct thrombin inhibitor ximelagatran.

View Article and Find Full Text PDF

Decyl-ubiquinone and decyl-plastoquinone were used as model compounds to test the potential effect of quinone derivatives on two enzymes of the vitamin K cycle in vitro. Substantial inhibition of gamma-glutamate carboxylase was found, whereas vitamin K-epoxide reductase was inhibited to a much lesser extent. The inhibitory effect of both decylquinones was eliminated in a time-dependent way by solubilized microsomes, but not by purified carboxylase.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!